US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ABPRO HLDGS INC

0.5220

0.0000

Volume:- -

Turnover:1.92M

Market Cap:1.42M

PE:-0.04

High:0.5220

Open:0.5220

Low:0.5220

Close:0.5220

52wk High:29.97

52wk Low:0.5171

Shares:2.72M

Float Shares:1.01M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-11.8955

EPS(LYR):-22.3097

ROE:-125.45%

ROA:-229.57%

PB:-0.09

PE(LYR):-0.02

Loading ...

Overview Company News Filings

AEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar Program

Nasdaq Orders Abpro Holdings Delisting for Minimum Equity Noncompliance

Nasdaq Warns Abpro Holdings of Possible Delisting Over Board Compliance Lapses

Abpro Holdings Directors Anthony Eisenberg and Sooyoung Lee Resign

Abpro Holdings Secures $147,000 Unsecured Loan from CEO to Fund D&O Insurance

Abpro Holdings announces ABP-102 featured in presentation

Abpro Holdings Receives FDA IND Clearance for ABP-102

Abpro’s Lead Program ABP-102 Featured in Celltrion Presentation at the 44th Annual J.P. Morgan Healthcare Conference

FDA Clears IND Application for Abpro's Lead Multispecific Antibody Cancer Candidate

Abpro Holdings Inc: Clinical Trial Anticipated to Commence in First Half of 2026 Through Abpro's Global Collaboration With Celltrion

THOMSON REUTERS

Abpro and Celltrion, Inc. Announce U.S. FDA Ind Clearance for Lead Multispecific Antibody Cancer Candidate Abp-102 / Ct-P72

THOMSON REUTERS

Abpro Holdings and Celltrion Submit IND for Phase 1 Trial of ABP-102/CT-P72 in HER2-Positive Cancers

Abpro Holdings Inc - Phase 1 Trial for Her2-Positive Cancers Expected in 1H 2026

THOMSON REUTERS

Abpro Holdings Announces Submission of an Ind Application to Initiate a Phase 1 Clinical Trial of T Cell Engager Abp-102/Ct-P72 for Her2-Positive Cancers

THOMSON REUTERS

Abpro Holdings Completes Reverse Stock Split

Abpro Holdings Files Prospectus Related To The Offer And Resale Of Up To 9.78 Million Shares Of Common Stock - SEC Filing

Press Release: AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth

BRIEF-Abpro Holdings Files Prospectus Related To The Offer And Resale Of Up To 9.78 Million Shares Of Common Stock - SEC Filing

Abpro Holdings: Files Prospectus Related to the Offer and Resale of up to 9.78 Mln Shares of Common Stock- SEC Filing

THOMSON REUTERS

Abpro and Celltrion Advance HER2×CD3 T-Cell Engager Toward Clinical Trials for HER2-Positive Cancers

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ABP/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ABP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ABP\",,,,,undefined,":{"symbol":"ABP","market":"US","secType":"STK","nameCN":"ABPRO HLDGS INC","latestPrice":0.522,"timestamp":1771621200000,"preClose":0.522,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":1006226,"shares":2716278,"eps":-11.895451,"marketStatus":"Delisted","change":0,"latestTime":"02-20 16:00:00 EST","open":0.522,"high":0.522,"low":0.522,"amount":1919809.5600011998,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-11.895451,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1526011200000,"exchange":"NASDAQ","adjPreClose":0.522,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ABP\",,,,,undefined,":{"symbol":"ABP","floatShares":1006226,"roa":"-229.57%","roe":"-125.45%","lyrEps":-22.309734,"shares":2716278,"dividePrice":0,"high":0.522,"amplitude":0,"preClose":0.522,"low":0.522,"week52Low":0.51705,"pbRate":"-0.09","week52High":29.97,"institutionHeld":0,"latestPrice":0.522,"eps":-11.895451,"divideRate":0,"volume":0,"delay":0,"ttmEps":-11.895451,"open":0.522},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ABP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-02-23","symbol":"ABP","reason":null,"defaultRemindTime":1771857000000,"announcedDate":"2026-02-20","type":"delisting","dateTimestamp":1771822800000},{"market":"US","date":"2025-11-14","symbol":"ABP","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1763096400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-11-03","symbol":"ABP","defaultRemindTime":1762180200000,"type":"split","dateTimestamp":1762146000000,"forFactor":30,"toFactor":1,"ratio":30}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ABP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ABP\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ABP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ABP","date":"2026-02-20","current":-0.043882,"percent":0.990415,"low":-23.177979,"twenty":-4.023113,"median":-1.432052,"eighty":-1.097413,"high":-0.133032,"avg":-2.801188,"sd":3.534508,"marketCap":2173294},"quantilePoints":[{"date":"2024-11-22","current":-19.866839,"twenty":-22.778143,"median":-21.303749,"eighty":-20.955892,"marketCap":160663127},{"date":"2024-11-29","current":-8.390781,"twenty":-21.853523,"median":-19.866839,"eighty":-18.304981,"marketCap":136412089},{"date":"2024-12-06","current":-4.81693,"twenty":-21.258393,"median":-18.273744,"eighty":-7.899765,"marketCap":78310643},{"date":"2024-12-13","current":-4.972315,"twenty":-20.411365,"median":-8.390781,"eighty":-5.307946,"marketCap":80836793},{"date":"2024-12-20","current":-4.630468,"twenty":-19.585704,"median":-7.054472,"eighty":-4.754776,"marketCap":75279264},{"date":"2024-12-27","current":-9.354167,"twenty":-19.01094,"median":-7.505088,"eighty":-4.779638,"marketCap":152074217},{"date":"2025-01-03","current":-4.879084,"twenty":-18.367455,"median":-7.054472,"eighty":-4.829361,"marketCap":79321103},{"date":"2025-01-10","current":-4.008929,"twenty":-18.117558,"median":-6.526163,"eighty":-4.754776,"marketCap":65174664},{"date":"2025-01-17","current":-4.195391,"twenty":-13.953559,"median":-5.562777,"eighty":-4.242006,"marketCap":68206044},{"date":"2025-01-24","current":-8.381212,"twenty":-10.274045,"median":-5.5317,"eighty":-4.189176,"marketCap":64669434},{"date":"2025-01-31","current":-6.744257,"twenty":-8.628186,"median":-6.060009,"eighty":-4.195391,"marketCap":52038685},{"date":"2025-02-07","current":-7.00617,"twenty":-8.401963,"median":-6.285909,"eighty":-4.232683,"marketCap":54059605},{"date":"2025-02-14","current":-6.6133,"twenty":-8.390781,"median":-6.457638,"eighty":-4.503052,"marketCap":51028225},{"date":"2025-02-21","current":-6.154953,"twenty":-8.38504,"median":-6.460736,"eighty":-4.568314,"marketCap":47491616},{"date":"2025-02-28","current":-3.797737,"twenty":-8.263352,"median":-6.416866,"eighty":-4.434578,"marketCap":29303337},{"date":"2025-03-07","current":-3.478858,"twenty":-8.177857,"median":-6.257426,"eighty":-4.18296,"marketCap":26842867},{"date":"2025-03-14","current":-3.080096,"twenty":-7.787294,"median":-5.687085,"eighty":-4.028744,"marketCap":23766017},{"date":"2025-03-21","current":-3.000867,"twenty":-7.524374,"median":-5.506113,"eighty":-3.915698,"marketCap":23154689},{"date":"2025-03-28","current":-2.695084,"twenty":-7.520626,"median":-4.979619,"eighty":-3.467596,"marketCap":20795265},{"date":"2025-04-04","current":-2.363764,"twenty":-7.50198,"median":-4.894623,"eighty":-3.339389,"marketCap":18238801},{"date":"2025-04-11","current":-1.71422,"twenty":-7.395956,"median":-4.754776,"eighty":-3.180932,"marketCap":13226920},{"date":"2025-04-17","current":-1.742819,"twenty":-7.202605,"median":-4.630468,"eighty":-3.128942,"marketCap":12604067},{"date":"2025-04-25","current":-2.345012,"twenty":-7.00617,"median":-4.528423,"eighty":-2.892566,"marketCap":16959130},{"date":"2025-05-02","current":-1.551534,"twenty":-6.927596,"median":-4.242006,"eighty":-2.702941,"marketCap":11220693},{"date":"2025-05-09","current":-1.374418,"twenty":-6.783544,"median":-4.179852,"eighty":-2.352513,"marketCap":9939792},{"date":"2025-05-16","current":-1.878135,"twenty":-6.694312,"median":-4.040006,"eighty":-2.089541,"marketCap":13582675},{"date":"2025-05-23","current":-1.041496,"twenty":-6.619394,"median":-4.01039,"eighty":-1.859432,"marketCap":11905342},{"date":"2025-05-30","current":-1.204886,"twenty":-6.618175,"median":-3.977852,"eighty":-1.811326,"marketCap":14163434},{"date":"2025-06-06","current":-1.097842,"twenty":-6.6133,"median":-3.797737,"eighty":-1.715791,"marketCap":12905137},{"date":"2025-06-13","current":-1.196095,"twenty":-6.589728,"median":-3.46478,"eighty":-1.630882,"marketCap":14060096},{"date":"2025-06-20","current":-1.080777,"twenty":-6.49544,"median":-3.411666,"eighty":-1.551534,"marketCap":12704539},{"date":"2025-06-27","current":-1.153174,"twenty":-6.482344,"median":-3.339389,"eighty":-1.416926,"marketCap":13555561},{"date":"2025-07-03","current":-0.972183,"twenty":-6.482344,"median":-3.198611,"eighty":-1.323927,"marketCap":11428007},{"date":"2025-07-11","current":-1.00683,"twenty":-6.447771,"median":-3.167836,"eighty":-1.217296,"marketCap":11835281},{"date":"2025-07-18","current":-1.014586,"twenty":-6.434171,"median":-3.123966,"eighty":-1.154034,"marketCap":11926462},{"date":"2025-07-25","current":-1.376052,"twenty":-6.420079,"median":-2.994646,"eighty":-1.153174,"marketCap":16175493},{"date":"2025-08-01","current":-1.336234,"twenty":-6.3121,"median":-2.818837,"eighty":-1.154034,"marketCap":15707431},{"date":"2025-08-08","current":-1.238499,"twenty":-6.285909,"median":-2.704251,"eighty":-1.166021,"marketCap":14558551},{"date":"2025-08-15","current":-1.639965,"twenty":-6.240336,"median":-2.685262,"eighty":-1.173707,"marketCap":20169933},{"date":"2025-08-22","current":-1.590427,"twenty":-6.169751,"median":-2.320925,"eighty":-1.191855,"marketCap":19560666},{"date":"2025-08-29","current":-1.588472,"twenty":-5.780659,"median":-2.226259,"eighty":-1.203128,"marketCap":19536616},{"date":"2025-09-05","current":-1.596946,"twenty":-5.6125,"median":-1.931607,"eighty":-1.214194,"marketCap":19640833},{"date":"2025-09-12","current":-1.061154,"twenty":-5.544131,"median":-1.862549,"eighty":-1.187614,"marketCap":13051133},{"date":"2025-09-19","current":-1.303629,"twenty":-5.500996,"median":-1.827834,"eighty":-1.181348,"marketCap":16033333},{"date":"2025-09-26","current":-1.39032,"twenty":-5.194246,"median":-1.77831,"eighty":-1.186042,"marketCap":17099550},{"date":"2025-10-03","current":-1.488744,"twenty":-4.989128,"median":-1.733827,"eighty":-1.192178,"marketCap":18310066},{"date":"2025-10-10","current":-1.287334,"twenty":-4.975237,"median":-1.708327,"eighty":-1.20137,"marketCap":15832916},{"date":"2025-10-17","current":-1.225411,"twenty":-4.935023,"median":-1.674511,"eighty":-1.199339,"marketCap":15071333},{"date":"2025-10-24","current":-1.304281,"twenty":-4.891515,"median":-1.660419,"eighty":-1.202667,"marketCap":16041350},{"date":"2025-10-31","current":-1.277556,"twenty":-4.841792,"median":-1.639965,"eighty":-1.214194,"marketCap":15712666},{"date":"2025-11-07","current":-1.217697,"twenty":-4.779638,"median":-1.630228,"eighty":-1.199339,"marketCap":14976457},{"date":"2025-11-14","current":-1.276251,"twenty":-4.754776,"median":-1.62238,"eighty":-1.201896,"marketCap":15696607},{"date":"2025-11-21","current":-1.432202,"twenty":-4.680191,"median":-1.603789,"eighty":-1.201896,"marketCap":16990210},{"date":"2025-11-28","current":-1.557,"twenty":-4.605606,"median":-1.597597,"eighty":-1.204115,"marketCap":18470690},{"date":"2025-12-05","current":-1.458543,"twenty":-4.568314,"median":-1.596946,"eighty":-1.21001,"marketCap":17302690},{"date":"2025-12-12","current":-1.357795,"twenty":-4.536401,"median":-1.58945,"eighty":-1.218131,"marketCap":16107528},{"date":"2025-12-19","current":-1.096769,"twenty":-4.434578,"median":-1.579998,"eighty":-1.204115,"marketCap":13010971},{"date":"2025-12-26","current":-1.083031,"twenty":-4.331319,"median":-1.565703,"eighty":-1.196744,"marketCap":12847994},{"date":"2026-01-02","current":-0.968545,"twenty":-4.242006,"median":-1.557,"eighty":-1.186302,"marketCap":11489855},{"date":"2026-01-09","current":-0.929621,"twenty":-4.195391,"median":-1.545517,"eighty":-1.160882,"marketCap":11028088},{"date":"2026-01-16","current":-0.815135,"twenty":-4.195391,"median":-1.511537,"eighty":-1.153174,"marketCap":9669949},{"date":"2026-01-23","current":-0.664862,"twenty":-4.170529,"median":-1.486355,"eighty":-1.146978,"marketCap":7887256},{"date":"2026-01-30","current":-0.446493,"twenty":-4.114591,"median":-1.470493,"eighty":-1.135385,"marketCap":5296742},{"date":"2026-02-06","current":-0.343456,"twenty":-4.052437,"median":-1.458543,"eighty":-1.111545,"marketCap":4074417},{"date":"2026-02-13","current":-0.189817,"twenty":-4.040006,"median":-1.451644,"eighty":-1.104358,"marketCap":2251794},{"date":"2026-02-20","current":-0.183199,"twenty":-4.023113,"median":-1.432052,"eighty":-1.097413,"marketCap":2173294}],"updateTime":1774687164170},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ABP\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622073916","title":"AEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2622073916","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622073916?lang=en_us&edition=fundamental","pubTime":"2026-03-25 20:00","pubTimestamp":1774440000,"startTime":"0","endTime":"0","summary":"FDA provided constructive feedback on Company’s analytical similarity strategy under the 351(k) biosimilar pathway Company continues to execute its analytical program and plans to request a BPD Type 2","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/25/3262144/0/en/AEON-Biopharma-Announces-FDA-Feedback-Following-BPD-Type-2a-Meeting-for-the-ABP-450-Biosimilar-Program.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABP","BK4139","BK4588","AEON","BK4585","LABU"],"gpt_icon":0},{"id":"2613297666","title":"Nasdaq Orders Abpro Holdings Delisting for Minimum Equity Noncompliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2613297666","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613297666?lang=en_us&edition=fundamental","pubTime":"2026-02-21 05:16","pubTimestamp":1771622190,"startTime":"0","endTime":"0","summary":"Abpro Holdings Inc. said it received notice from a Nasdaq Hearings Panel that its securities will be delisted and trading suspended on Feb. 23, 2026, after the company failed to meet the minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550 by the Feb. 16 deadline. The company said it expects to appeal the decision and, if trading is suspended, its common stock and public warrants would be eligible for quotation on the OTC Pink Market, though it warned of potentially reduced liquidity and transparency.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abpro Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nNDL5tBxnc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABPO","BK4139","ABP"],"gpt_icon":0},{"id":"2610695039","title":"Nasdaq Warns Abpro Holdings of Possible Delisting Over Board Compliance Lapses","url":"https://stock-news.laohu8.com/highlight/detail?id=2610695039","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610695039?lang=en_us&edition=fundamental","pubTime":"2026-02-12 05:17","pubTimestamp":1770844675,"startTime":"0","endTime":"0","summary":"Abpro Holdings Inc. is facing potential delisting from the Nasdaq Stock Market due to noncompliance with several Nasdaq Listing Rules following the recent resignations of two board members. The company no longer meets requirements for board and committee independence, including rules mandating a majority of independent directors and minimum independent membership on the audit and compensation committees. While the company’s stock remains listed for now, the Nasdaq Hearings Panel will consider these deficiencies in its ongoing review of Abpro’s continued listing. The company is working to appoint qualified independent directors to restore compliance within the required timeframes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abpro Hol","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nNDL6rDJMq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABP","BK4139"],"gpt_icon":0},{"id":"2608604388","title":"Abpro Holdings Directors Anthony Eisenberg and Sooyoung Lee Resign","url":"https://stock-news.laohu8.com/highlight/detail?id=2608604388","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608604388?lang=en_us&edition=fundamental","pubTime":"2026-02-04 05:17","pubTimestamp":1770153446,"startTime":"0","endTime":"0","summary":"Abpro Holdings Inc. announced that Anthony D. Eisenberg and Sooyoung Lee have resigned from the company's Board of Directors and all Board committees. The company is in the process of identifying new independent directors to fill the vacancies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abpro Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 03, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL6CRRvl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ABP"],"gpt_icon":0},{"id":"2606973462","title":"Abpro Holdings Secures $147,000 Unsecured Loan from CEO to Fund D&O Insurance","url":"https://stock-news.laohu8.com/highlight/detail?id=2606973462","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606973462?lang=en_us&edition=fundamental","pubTime":"2026-01-26 15:47","pubTimestamp":1769413672,"startTime":"0","endTime":"0","summary":"Abpro Holdings Inc. has entered into a new loan agreement with its Chief Executive Officer and Chairman, Miles J.W. Suk. Under the terms of the agreement, Suk will provide an unsecured loan of $147,000 to the company, specifically to fund the premium for its directors' and officers' liability insurance. The loan, which features a nine-month term, does not accrue interest for the first three months, after which it bears interest at a variable rate equal to the three-month Term SOFR plus 2.0% per annum. The loan may be prepaid at any time without penalty and is not secured by collateral or guaranteed by any third party.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abpro Holdings Inc. published the original content used to generate this","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDL2fGyWn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABP","BK4139"],"gpt_icon":0},{"id":"2603460296","title":"Abpro Holdings announces ABP-102 featured in presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2603460296","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603460296?lang=en_us&edition=fundamental","pubTime":"2026-01-15 20:10","pubTimestamp":1768479055,"startTime":"0","endTime":"0","summary":"Abpro Holdings (ABP) announced that its lead multispecific antibody oncology program, ABP-102 / CT-P72, was featured in a presentation by its globa...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/abpro-holdings-announces-abp-102-featured-in-presentation-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/abpro-holdings-announces-abp-102-featured-in-presentation-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABP","BK4139"],"gpt_icon":0},{"id":"2603047726","title":"Abpro Holdings Receives FDA IND Clearance for ABP-102","url":"https://stock-news.laohu8.com/highlight/detail?id=2603047726","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603047726?lang=en_us&edition=fundamental","pubTime":"2026-01-15 20:00","pubTimestamp":1768478431,"startTime":"0","endTime":"0","summary":"Abpro Holdings Inc. announced that its lead multispecific antibody oncology program, ABP-102 / CT-P72, recently received Investigational New Drug  clearance from the U.S. Food and Drug Administration . This regulatory approval enables the initiation of a global Phase 1 clinical trial to evaluate ABP-102 / CT-P72 in patients with HER2-positive solid tumors. The study is expected to commence in the first half of 2026 through Abpro's strategic collaboration with Celltrion.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abpro Holdings Inc. published the original content used to generate this news brief via GlobeNewswire  on January 15, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nNDLc5nrYr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2210149790.SGD","SG9999014021.USD","BK4112","ABP","IE00B64PRP62.GBP","LU2095319765.USD","SG9999014013.SGD","LU2210150020.SGD","BK4139","BK4588","NDAQ","SG9999014005.SGD","LU0314104364.USD","SG9999014039.USD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2603602504","title":"Abpro’s Lead Program ABP-102 Featured in Celltrion Presentation at the 44th Annual J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2603602504","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603602504?lang=en_us&edition=fundamental","pubTime":"2026-01-15 20:00","pubTimestamp":1768478400,"startTime":"0","endTime":"0","summary":"Recently IND-Cleared HER2 × CD3 T-Cell Engager Highlighted by Global Biopharmaceutical PartnerBURLINGTON, Mass., Jan.  15, 2026  (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq: ABP), a clinical-stag","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/15/3219396/0/en/Abpro-s-Lead-Program-ABP-102-Featured-in-Celltrion-Presentation-at-the-44th-Annual-J-P-Morgan-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0557290698.USD","LU0528227936.USD","LU0795875086.SGD","BK4605","LU1880398471.USD","LU0823421416.USD","BK4080","LU0823421333.USD","BK4588","LU1244550221.USD","LU1861558580.USD","LU1852331112.SGD","LU0823434583.USD","LU0912757837.SGD","BK4141","BK4137","LU2089985449.USD","IE00BMPRXN33.USD","BK4581","LU1242518931.SGD","LU0109392836.USD","LU2023251221.USD","LU2089284900.SGD","LU0314104364.USD","LU0198837287.USD","LU0719512351.SGD","IE00BKVL7J92.USD","LU0006306889.USD","IE0004445239.USD","LU2133065610.SGD","LU2250418816.HKD","IE00B5949003.HKD","LU2054465674.USD","LU0979878070.USD","LU2931357623.SGD","LU1363072403.SGD","BK4516","LU0029874061.USD","LU0234570918.USD","LU1989764664.SGD","LU0274383776.USD","LU0106831901.USD","LU1803068979.SGD","IE0009356076.USD","LU2360106780.USD","BK4512","LU1668664300.SGD","LU2355687059.USD","LU0098860793.USD","IE00BZ1G4Q59.USD","LU0106261372.USD","BK4612","BK4231","LU2271345857.HKD","LU0889565833.HKD","ABP","BK4532","LU1720051017.SGD","LU1861559042.SGD","LU1989772840.SGD","LU2028103732.USD","LU2347655156.SGD","LU0267386448.USD","LU2264538146.SGD","LU0320765646.SGD","LU0128526141.USD","LU1548497426.USD","LU0971096721.USD","LU1951198990.SGD","LU0642271901.SGD","LU1791710400.SGD","LU0390134368.USD","LU0795875169.SGD","LU0082616367.USD","BK4534","XBI","LU0823434740.USD","LU0081259029.USD","LU1316542783.SGD","LU1242518857.USD","LU1923623000.USD","LU1989772923.USD","LU1880398554.USD","LU1064131342.USD","LU0056508442.USD","LU2089283258.USD","LU0158827781.USD","BK4529","BK4575","LU1732800096.USD","LU2458330169.SGD","IE00BMPRXR70.SGD","LU2458330243.SGD","LU1074936037.SGD","LU1244550577.SGD","LU1791710582.SGD","LU2357305700.SGD","BK4127","LU1303367103.USD","LABU","LU0882574139.USD","BK4614","LU1732799900.SGD","BK4504","BK4139","LU0127658192.USD","LU1244550494.USD","BK4585","LU0158827948.USD","LU2098885051.SGD","LU1162221912.USD","LU1951200564.SGD","BK4573","LU1720051108.HKD","LU1988902786.USD","LU2111349929.HKD","LU0225283273.USD","BK4566","BK4543","BK4554"],"gpt_icon":0},{"id":"2601789487","title":"FDA Clears IND Application for Abpro's Lead Multispecific Antibody Cancer Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2601789487","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601789487?lang=en_us&edition=fundamental","pubTime":"2026-01-06 20:00","pubTimestamp":1767700824,"startTime":"0","endTime":"0","summary":"Abpro Holdings Inc. and Celltrion, Inc. have received U.S. FDA clearance for the Investigational New Drug  application of their lead multispecific antibody cancer candidate, ABP-102 / CT-P72. This regulatory approval enables the initiation of a Phase 1 clinical trial targeting HER2-positive solid tumors, with the study anticipated to begin in the first half of 2026. The trial, led by Celltrion, will assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of the therapy as part of a global collaboration between the two companies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abpro Holdings Inc. published the original content used to generate this news brief via GlobeNewswire  on January 06, 2026, and is solely respo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDLbprgcp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SG9999014013.SGD","LU2210150020.SGD","ABP","BK4588","SG9999014005.SGD","LU2210149790.SGD","IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4112","IE00B3QW5Z07.USD","NDAQ","LU0314104364.USD","SG9999014039.USD","IE00BGHQF748.EUR","LU2095319765.USD","BK4139","SG9999014021.USD"],"gpt_icon":0},{"id":"2601894856","title":"Abpro Holdings Inc: Clinical Trial Anticipated to Commence in First Half of 2026 Through Abpro's Global Collaboration With Celltrion","url":"https://stock-news.laohu8.com/highlight/detail?id=2601894856","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601894856?lang=en_us&edition=fundamental","pubTime":"2026-01-06 20:00","pubTimestamp":1767700803,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nTUAG7BSV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ABP","BK4139"],"gpt_icon":0},{"id":"2601894839","title":"Abpro and Celltrion, Inc. Announce U.S. FDA Ind Clearance for Lead Multispecific Antibody Cancer Candidate Abp-102 / Ct-P72","url":"https://stock-news.laohu8.com/highlight/detail?id=2601894839","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601894839?lang=en_us&edition=fundamental","pubTime":"2026-01-06 20:00","pubTimestamp":1767700803,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nTUAG7BSV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ABP","BK4139"],"gpt_icon":0},{"id":"2591645306","title":"Abpro Holdings and Celltrion Submit IND for Phase 1 Trial of ABP-102/CT-P72 in HER2-Positive Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2591645306","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591645306?lang=en_us&edition=fundamental","pubTime":"2025-12-15 20:00","pubTimestamp":1765800019,"startTime":"0","endTime":"0","summary":"Abpro Holdings Inc., in collaboration with Celltrion, Inc., has submitted an investigational new drug  application to the U.S. Food and Drug Administration  for ABP-102/CT-P72, a HER2 × CD3 T cell engager designed for improved selectivity in treating HER2-positive cancers. The IND submission supports the initiation of a phase 1 clinical trial, anticipated to begin in the first half of 2026, pending FDA regulatory clearance. This marks the first IND submission by Abpro for a solid tumor indication and represents a key milestone in the joint development efforts between Abpro and Celltrion.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abpro Holdings Inc. published the original content used to generate this news brief via GlobeNewswire  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL3x9Xkh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","SG9999014039.USD","LU2210149790.SGD","LU2210150020.SGD","SG9999014013.SGD","BK4112","SG9999014005.SGD","IE00B3QW5Z07.USD","SG9999014021.USD","NDAQ","BK4585","IE00B64PRP62.GBP","LU0314104364.USD","LU2095319765.USD","IE00BKPKM429.USD","ABP","BK4588","BK4139"],"gpt_icon":0},{"id":"2591964593","title":"Abpro Holdings Inc - Phase 1 Trial for Her2-Positive Cancers Expected in 1H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2591964593","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591964593?lang=en_us&edition=fundamental","pubTime":"2025-12-15 20:00","pubTimestamp":1765800000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nTUABBBV7Y:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ABP","BK4139"],"gpt_icon":0},{"id":"2591455626","title":"Abpro Holdings Announces Submission of an Ind Application to Initiate a Phase 1 Clinical Trial of T Cell Engager Abp-102/Ct-P72 for Her2-Positive Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2591455626","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591455626?lang=en_us&edition=fundamental","pubTime":"2025-12-15 20:00","pubTimestamp":1765800000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nTUABBBV7Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ABP","BK4139"],"gpt_icon":0},{"id":"2590343411","title":"Abpro Holdings Completes Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2590343411","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590343411?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:00","pubTimestamp":1765281629,"startTime":"0","endTime":"0","summary":"Abpro Holdings Inc. recently completed a reverse stock split as part of its ongoing strategy to maintain compliance with Nasdaq listing requirements. The move is included in the company's broader compliance roadmap, which also involves a market transfer application and planned capital strategy to increase stockholders' equity.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abpro Holdings Inc. published the original content used to generate this news brief via GlobeNewswire  on December 09, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDLbVnBdl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LU0314104364.USD","IE00B64PRP62.GBP","LU2210150020.SGD","ABP","BK4588","BK4585","BK4112","LU2095319765.USD","LU2210149790.SGD","NDAQ","IE00BKPKM429.USD","SG9999014021.USD","BK4139","SG9999014039.USD","SG9999014013.SGD"],"gpt_icon":0},{"id":"2584292839","title":"Abpro Holdings Files Prospectus Related To The Offer And Resale Of Up To 9.78 Million Shares Of Common Stock - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2584292839","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584292839?lang=en_us&edition=fundamental","pubTime":"2025-11-20 01:06","pubTimestamp":1763571975,"startTime":"0","endTime":"0","summary":"Nov 7 (Reuters) - ABPRO Holdings Inc ::*ABPRO HOLDINGS:  FILES PROSPECTUS RELATED TO THE OFFER AND RESALE OF UP TO 9.78 MILLION SHARES OF COMMON STOCK- SEC FILING  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 07-NOV-202512:47:40 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD7xwYZZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABP","BK4139"],"gpt_icon":0},{"id":"2583092285","title":"Press Release: AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2583092285","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583092285?lang=en_us&edition=fundamental","pubTime":"2025-11-14 21:30","pubTimestamp":1763127000,"startTime":"0","endTime":"0","summary":"-- FDA Type 2a meeting scheduled for November 19, 2025, to review AEON's analytical development plan and initial data --. -- Positive biosimilarity data for ABP-450 confirming identical amino-acid sequencing and highly similar functional characteristics submitted to FDA ahead of scheduled Type 2a meeting --. -- Two complementary financing transactions announced in November 2025 - $6 million PIPE financing and a proposed Daewoong note exchange - are expected to strengthen AEON's balance sheet, reduce outstanding debt by more than 90%, accelerate the ABP-450 biosimilar program by up to six months, and extend cash runway into the second quarter of 2026 --. \"The foundation of AEON's progress lies in our science and is underscored by years of market validation\", said Rob Bancroft, AEON's President and Chief Executive Officer. \"Our recently released analytical results confirm both ABP-450's identical amino-acid sequencing of all visible portions and highly similar functional characteristics ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AEON","R","ABP","BK4232","BK4022","BK4139"],"gpt_icon":0},{"id":"2581007440","title":"BRIEF-Abpro Holdings Files Prospectus Related To The Offer And Resale Of Up To 9.78 Million Shares Of Common Stock - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2581007440","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581007440?lang=en_us&edition=fundamental","pubTime":"2025-11-07 20:47","pubTimestamp":1762519660,"startTime":"0","endTime":"0","summary":"BRIEF-Abpro Holdings Files Prospectus Related To The Offer And Resale Of Up To 9.78 Million Shares Of Common Stock - SEC FilingNov 7  - ABPRO Holdings Inc ABP.O:ABPRO HOLDINGS:  FILES PROSPECTUS RELATED TO THE OFFER AND RESALE OF UP TO 9.78 MILLION SHARES OF COMMON STOCK- SEC FILINGSource text: [ID:n0001213900-25-107374]Further company coverage: ABP.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nFWN3WJ0Y6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ABP"],"gpt_icon":0},{"id":"2581000279","title":"Abpro Holdings:  Files Prospectus Related to the Offer and Resale of up to 9.78 Mln Shares of Common Stock- SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2581000279","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581000279?lang=en_us&edition=fundamental","pubTime":"2025-11-07 20:44","pubTimestamp":1762519451,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nFWN3WJ0Y6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ABP","BK4139"],"gpt_icon":0},{"id":"2580735578","title":"Abpro and Celltrion Advance HER2×CD3 T-Cell Engager Toward Clinical Trials for HER2-Positive Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2580735578","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580735578?lang=en_us&edition=fundamental","pubTime":"2025-11-04 20:04","pubTimestamp":1762257883,"startTime":"0","endTime":"0","summary":"Abpro Holdings Inc. announced that new preclinical data for CT-P72/ABP-102, a tetravalent bispecific antibody targeting HER2 and CD3, will be presented at the Society for Immunotherapy of Cancer  2025 Annual Meeting. The poster presentation has been selected as one of the Top 150 abstracts out of more than 1,300 submissions. CT-P72/ABP-102 demonstrated potent and selective anti-tumor activity in HER2-high models, including tumors resistant to Enhertu, and showed reduced on-target, off-tumor activity, supporting a favorable preclinical safety profile. The findings support advancement toward clinical development in HER2-positive cancers, with plans to initiate a first-in-human trial next year.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advic","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDL5zpytw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABP","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":34,"code":"91000000","status":"200"}]}}